EUVIMEDEUVIMED entdecken
Multizentrische Studie

Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study

Carmen Yagüe Caballero iD, Santiago García López iD, Ana Royo Esteban, Laura Figueras Panillo iD, Pilar Nos iD, Luisa de Castro iD, M Dolores Martín-Arranz, Manuel Barreiro-de Acosta iD, Elena Ricart iD, Ruth de Francisco iD, Eva Iglesias iD, Antonio Giordano iD und 48 weitere

Alimentary Pharmacology & Therapeutics · 2026-11 · 64 (9) · 1234-1247

DOI: 10.1111/apt.70904 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 12.08.2026. Verfasst von Carmen Yagüe Caballero und 59 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Zaragoza, Spain. Hauptthemen laut MEDLINE: Tumor Necrosis Factor-alpha, Inflammatory Bowel Diseases, Crohn Disease, Gastrointestinal Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Eusko Jaurlaritza.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The expanding use of targeted therapies in inflammatory bowel disease has made treatment sequencing increasingly relevant, yet evidence on anti‐TNF effectiveness after prior biologics with different mechanisms of action (MOA) remains limited. Our objective is to evaluate the durability of anti‐TNF treatment in this scenario.

Methods

Multicentre study based on data from the ENEIDA registry. Patients who received second‐line anti‐TNF therapy after a first biologic with a different MOA for active luminal disease were identified. Using propensity score matching, each case was matched with three controls from two cohorts: patients treated with second‐line anti‐TNF after another anti‐TNF and patients receiving first‐line anti‐TNF therapy. Treatment durability and short‐ and long‐term clinical effectiveness were assessed.

Results

Sixty‐six Crohn's disease patients and 117 UC patients receiving anti‐TNF after other MOA were included. In CD, second‐line anti‐TNF therapy after a different MOA (62% ustekinumab) was associated with a higher risk of treatment discontinuation compared with first‐line anti‐TNF therapy (HR 1.55; 95% CI, 1.05–2.30), without significant differences in short‐ or long‐term clinical effectiveness. In UC, anti‐TNF therapy after a different MOA (90% vedolizumab) was associated with lower treatment durability compared with first‐line anti‐TNF therapy (HR 1.69; 95% CI, 1.31–2.19) and with anti‐TNF after another anti‐TNF agent (HR 1.91; 95% CI, 1.48–2.48), its remission rates significantly lower at both short‐ and long‐term follow‐up ( p < 0.001).

Conclusions

Anti‐TNF therapy used after a different MOA is associated with reduced effectiveness and durability compared with its use as first‐line therapy or after another anti‐TNF agent, especially in UC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor Necrosis Factor-alphaInflammatory Bowel DiseasesCrohn DiseaseGastrointestinal AgentsColitis, UlcerativeBiological ProductsHumansFemaleRegistriesMaleAdultTreatment OutcomeMiddle AgedAntibodies, Monoclonal, HumanizedInfliximabUstekinumabAdalimumabPropensity Score

Stichwörter der Autor:innen

Crohn's diseaseanti‐TNF therapyinflammatory bowel diseasemechanism of actiontreatment sequencingulcerative colitis

Substanzen

Tumor Necrosis Factor-alphaAntibodies, Monoclonal, HumanizedInfliximabUstekinumabGastrointestinal AgentsAdalimumabBiological Products

Autor:innen und Institutionen

  • Servicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Instituto de investigación Sanitaria de Aragón, Zaragoza, Spain.
  • Servicio de aparato Digestivo, Hospital Uniersitari i Politècnic La fe, Instituto de investigación Sanitaria La Fe, València, Spain.
  • Servicio de Aparato Digestivo, Hospital Álvaro Cunqueiro, Vigo, Spain.
  • Servicio de Aparato Digestivo, Hospital Universiario La Paz, Madrid, Spain.
  • Servicio de Aparato Digestivo, Hospital Clínico Universitario de Santiago de Compostela, Health Research Institute of Santiago de Compostela (IDIS), Santiago de Compostela, Spain.

ORCID-Profile: Carmen Yagüe Caballero, Santiago García López, Laura Figueras Panillo, Pilar Nos, Luisa de Castro, Manuel Barreiro-de Acosta, Elena Ricart, Ruth de Francisco, Eva Iglesias, Antonio Giordano, Pilar Varela, Iago Rodríguez-Lago, Montserrat Rivero, Beatriz Sicilia, Jordi Guardiola, Jesús Barrio, Margalida Calafat, Ana Gutiérrez, Xavier Calvet, David Rafael de la Cruz, Francisco Mesonero, Cristina Martínez Pascual, Javier P Gisbert, Carla J Gargallo-Puyuelo, Cristina Rodríguez-Gutiérrez, Rufo Lorente, Lucía Márquez-Mosquera, José M Huguet, Laura Ramos, Ángel Ponferrada-Díaz, Daniel Ceballos, Mª Teresa Diz-Lois Palomares, Eva Sesé Abizanda, Pablo Vega, Ramón Pajares, Javier Santos Fernández, Elena Betoré, Yamile Zabana, Nuria Jiménez

Förderung

  • Instituto de Salud Carlos III
  • Eusko Jaurlaritza

Zitieren

APA

Yagüe Caballero, C., García López, S., Royo Esteban, A., Figueras Panillo, L., Nos, P., de Castro, L., Martín-Arranz, M. D., Barreiro-de Acosta, M., Ricart, E., de Francisco, R., Iglesias, E., Giordano, A., Varela, P., Rodríguez-Lago, I., Rivero, M., Sicilia, B., Navarro-Llavat, M., Vera, I., Suria, C., …, & Bujanda, L. (2026). Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study. Alimentary Pharmacology & Therapeutics, 64(9), 1234-1247. https://doi.org/10.1111/apt.70904

Vancouver

Yagüe Caballero C, García López S, Royo Esteban A, Figueras Panillo L, Nos P, de Castro L, et al. Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study. Alimentary Pharmacology & Therapeutics. 2026;64(9):1234-1247. doi:10.1111/apt.70904

BibTeX
@article{YageCaballero2026,
  author = {Yagüe Caballero, Carmen and García López, Santiago and Royo Esteban, Ana and Figueras Panillo, Laura and Nos, Pilar and de Castro, Luisa and Martín-Arranz, M Dolores and Barreiro-de Acosta, Manuel and Ricart, Elena and de Francisco, Ruth and Iglesias, Eva and Giordano, Antonio and Varela, Pilar and Rodríguez-Lago, Iago and Rivero, Montserrat and Sicilia, Beatriz and Navarro-Llavat, Merce and Vera, Isabel and Suria, Carles and Guardiola, Jordi and Barrio, Jesús and Calafat, Margalida and Gutiérrez, Ana and Calvet, Xavier and de la Cruz, David Rafael and Mesonero, Francisco and Martínez Pascual, Cristina and P Gisbert, Javier and Gargallo-Puyuelo, Carla J and Monfort I Miquel, David and Sierra, Mónica and Arranz, Laura and Rodríguez-Gutiérrez, Cristina and Lorente, Rufo and Bermejo, Fernando and Márquez-Mosquera, Lucía and Torres Vicente, Gisela and Pérez-Calle, José Lázaro and Huguet, José M and Ramos, Laura and Ponferrada-Díaz, Ángel and Ceballos, Daniel and Diz-Lois Palomares, Mª Teresa and Sesé Abizanda, Eva and Vega, Pablo and Pajares, Ramón and Santos Fernández, Javier and Betoré, Elena and Busquets, David and Merino, Olga and Martínez-Flores, Carlos and Zabana, Yamile and Sampedro González, Manuela Josefa and Ortiz de Zarate, Jone and Fuentes Coronel, Ana and Sainz Arnau, Empar and Carpio, Daniel and Jiménez, Nuria and Marín-Jiménez, Ignacio and Bujanda, Luis},
  title = {Impact of Prior Biologic Mechanism of Action on Anti‐ TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {64},
  number = {9},
  pages = {1234--1247},
  doi = {10.1111/apt.70904}
}
Kostenlos starten →